Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announced earnings guidance for the year ended December 31, 2019. For the year, it is expected that the net profit of the Group will record an increase of over 50% as compared to that for the year ended 31 December 2018.